NIH UH2/UH3 Phased Cooperative Agreement – From Feasibility to Full-Scale Implementation
The NIH UH2/UH3 Phased Cooperative Agreement mechanism supports scientific programs that require early-stage feasibility testing (UH2) before advancing into full-scale implementation (UH3). This structure is particularly valuable for translational science, behavioral interventions, emerging biomedical technologies, methodological innovation, clinical readiness frameworks, and programs requiring validation before expansion across sites or populations. Unlike traditional single-phase mechanisms, the UH2/UH3 model ensures that further investment is contingent upon the successful achievement of predefined, rigorously evaluated milestones.
During the UH2 feasibility phase, investigators refine study methods, validate technology approaches, confirm recruitment strategies, build data systems, establish collaborative frameworks, or conduct early operational testing. The UH2 phase is milestone-driven: the project must demonstrate feasibility, usability, performance thresholds, or other quantifiable criteria before the UH3 phase may activate. NIH program staff often participate in milestone assessment, ensuring scientific rigor and alignment with programmatic goals.
When UH2 milestones are met, the program transitions into the UH3 implementation phase, supporting broader scale deployment, advanced testing, expanded scientific aims, data collection, multi-site coordination, stakeholder engagement, or real-world use. The phased structure reduces scientific and logistical risk, enabling NIH to support high-impact programs while ensuring early validation.
Eligibility
UH2/UH3 applications may be submitted by:
U.S. academic institutions and medical schools
Nonprofit research organizations
Qualified for-profit entities, including technology, biomedical, clinical research, and translational analytics companies
Foreign institutions when allowed by the FOA
National or multi-site consortia requiring coordinated execution
Applicants must demonstrate the capacity for milestone-driven planning, data management, technical execution, and effective collaboration with NIH program leadership.
Review Considerations
Reviewers evaluate:
Feasibility and rigor of proposed UH2 milestones
Scientific merit, innovation, and translational value
Institutional capacity, governance, and administrative infrastructure
Data coordination, analytics, or methodological robustness
The program’s potential for major public health impact
Sound planning for UH3 implementation and scalability
Strong proposals clearly define milestones, success criteria, risk mitigation strategies, scalability plans, and measurable transition metrics.
How ScienceDocs Helps
ScienceDocs supports UH2/UH3 applicants with milestone development, feasibility testing strategy, translational narrative construction, data coordination planning, and polished proposal development—ensuring the phased mechanism is fully leveraged for competitive positioning.
To request expert UH2/UH3 assistance, visit:
https://www.sciencedocs.com/quotes